Liposomal NAD+ is one of the more expensive and heavily promoted forms available on the NAD+ supplement market. Products in this category are offered by Quicksilver Scientific, Cymbiotika, RHO, Renue by Science, Goldman Laboratories, and other brands, among others.
The main marketing argument is better absorption.
The premise is that encapsulating NAD+ in a lipid carrier can protect the molecule as it passes through the digestive tract and potentially improve its delivery compared to standard oral NAD+.
From the point of view of formulation technology, this is a rational concept.
The most important question, however, is whether the liposomal delivery method actually provides a significant advantage in humans, or is merely a more technologically advanced formulation concept.
In this article, we explain why unmodified oral NAD+ encounters absorption problems, what the purpose of liposomal encapsulation is, how liposomal NAD+ compares to standard capsules and sublingual products, what laboratory research currently shows, and what human study data is still lacking.
Why does oral NAD+ have an absorption problem?
Unmodified NAD+ is not ideally suited for simple absorption when taken orally, because it is a relatively large, highly charged, and water-soluble molecule.
These properties create several barriers that the molecule must overcome before reaching the systemic circulation.
The molecular mass of NAD+ is approximately 663 daltons. [1]
Its size and strong negative charge hinder passive transport across the intestinal epithelium compared to many smaller and less polar compounds.
The intestinal wall acts as a selective barrier.
Smaller substances with properties more compatible with cell membranes typically penetrate them more easily than large and heavily charged molecules, such as NAD+.
There is also a second problem.
The gastrointestinal tract and liver contain enzymes that actively break down NAD+ and related molecules as part of normal nucleotide and coenzyme metabolism.
This means that an orally administered NAD+ molecule must overcome both physical barriers of absorption and enzymatic degradation.
Even smaller NAD+ precursors, such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), undergo significant metabolic transformations during digestion and the first-pass hepatic effect before reaching systemic circulation. [1,2]
Unmodified NAD+ enters the same metabolic environment, yet it has a larger molecular structure and properties that are less favorable for passive absorption.
This connection helps explain why most clinical studies on NAD+ supplementation focus on precursors rather than on oral NAD+ in its unchanged form.
NR and NMN are smaller molecules that, once absorbed, can enter the NAD+ biosynthesis pathways in the body.
Liposomal NAD+ uses a different strategy.
Instead of altering the administered molecule, liposomal formulations are designed to improve the delivery of unchanged NAD+ by protecting it as it passes through the digestive tract.
What exactly does “liposomal delivery” mean?
A liposome is a microscopic structure formed from a lipid bilayer.
You can think of it as a small vesicle made of lipids that encloses an internal space.
Water-soluble substances, such as NAD+, could theoretically be trapped in this space.
This type of delivery technology has real pharmaceutical applications.
Liposomal formulations are used in certain approved drugs, including some anticancer drugs, where encapsulation can alter drug distribution, protect the active ingredient, or reduce specific side effects.
The proposed benefit for NAD+ is based on the same general principle.
The lipid layer is designed to protect the NAD+ molecule from adverse conditions in the gastrointestinal tract.
In theory, this may limit degradation caused by the stomach environment and digestive enzymes before the molecule has a chance to be absorbed.
A second potential benefit is its effect on cellular uptake.
Cell membranes also consist largely of lipid bilayers.
Because liposomes have a similar membrane structure, they may interact with cells differently than free, water-soluble NAD+.
In theory, liposomes can bind to cell membranes or be taken up through other transport mechanisms, potentially delivering their contents more effectively.
As a result, the concept of liposomal NAD+ is scientifically sound.
It also differs from attempts to passively transport unmodified NAD+ through the skin using a simple transdermal patch.
However, a biologically plausible mechanism of action is not the same as proven clinical benefit.
Whether liposomal NAD+ is actually more effective must be demonstrated in pharmacokinetic and clinical studies in humans.
Liposomal NAD+ vs standard capsules and sublingual NAD+
These three formats use different strategies to influence the availability of NAD+.
| Feature | Standard oral capsule | Tablet or sublingual lozenge | Liposomal formulation |
|---|---|---|---|
| What does it usually contain | An NAD+ precursor, such as NR, NMN, niacin, or nicotinamide; sometimes unmodified NAD+ | A NAD+ precursor or, less commonly, unchanged NAD+ | NAD+ or a precursor enclosed in a lipid bilayer |
| Assumed route of absorption | Standard absorption in the digestive tract | Presumed partial absorption through the oral mucosa | Delivery via the gastrointestinal tract using lipid encapsulation to protect the active ingredient |
| Mechanistic rationale for unchanged NAD+ | Weaker due to their size and NAD+ content; better documented for NR and NMN | Theoretically possible, but NAD+-specific absorption is poorly characterized. | Reliable, because lipid encapsulation can protect a large, charged, and water-soluble molecule [1] |
| Randomized clinical trials | More potent for NR and NMN, with numerous placebo-controlled studies [3,4] | No dedicated comparative studies on NAD+ absorption have been identified. | There is a lack of sufficient peer-reviewed clinical data confirming the bioavailability or superiority of liposomal NAD+ |
| Supporting laboratory tests | Comprehensive Resources for Biology: NR and NMN | Limited | Cell culture studies support the biological rationale for the liposomal formulation [5] |
| Relative cost | Usually the lowest | Moderate | Usually the highest among oral forms |
The table illustrates an important distinction.
Standard capsules have the strongest evidence base, but this evidence primarily pertains to NR and NMN, rather than unchanged NAD+.
Liposomal products aim to address a different problem: the effective delivery of unchanged NAD+.
Do studies show that liposomal NAD+ is more effective?
Currently, there is insufficient peer-reviewed clinical evidence to conclude that liposomal NAD+ is more effective than standard oral NAD+, NR, or NMN.
The theoretical rationale for the use of liposomes is sound.
Lipid encapsulation can protect a water-soluble substance, affect its stability, and alter the way it interacts with cell membranes.
However, the likely mechanism does not automatically confirm greater bioavailability in humans.
Demonstrating such an advantage would require pharmacokinetic studies measuring NAD+ and its metabolites in blood, cells, or tissues after comparable doses of different formulations.
Randomized clinical trials would also have to evaluate not only biomarkers, but also meaningful functional outcomes.
Based on current evidence, it cannot be confirmed that liposomal NAD+ improves energy levels, physical performance, cognitive function, metabolism, parameters related to biological aging, or other health markers.
What do the laboratory tests show?
Additional information is provided by cell culture studies.
One study compared liposomal and non-liposomal NAD+ in cultured human endothelial cells and keratinocytes. [5]
The liposomal formulation induced stronger effects with respect to some cellular markers associated with cellular senescence.
This supports the concept that lipid encapsulation can alter the way NAD+ interacts with cells.
However, it was an in vitro study.
Cell culture does not reproduce the full biological process that occurs after a human swallows the product.
Digestion, intestinal absorption, hepatic metabolism, circulation, tissue distribution, and cellular uptake create additional barriers that are absent in a cell culture experiment.
Laboratory results therefore support the biological plausibility of this concept.
However, they do not prove that the same effects occur in a living human body.
What evidence is still missing?
The most important missing evidence is a completed, peer-reviewed, human head-to-head comparative study.
Among the identified studies, no publications directly comparing equivalent doses were found:
- liposomal NAD+;
- standard non-liposomal NAD+;
- oral NMN;
- oral NR.
Without such a study, it is difficult to determine which delivery method results in the greatest increase in NAD+ in the blood, cells, or tissues per milligram administered.
It is also unknown which form provides the most lasting effect.
Most importantly, there is a lack of strong evidence showing that liposomal NAD+ provides better functional health outcomes than standard NAD+ precursors.
The current proposal must therefore remain limited.
Liposomal NAD+ has a biologically plausible rationale and is supported by cell culture studies, but its bioavailability, clinical efficacy, and advantages over the more extensively studied oral NR or NMN have not been established.
Which brands offer liposomal NAD+?
Several brands sell products marketed as liposomal NAD+.
These include Quicksilver Scientific, Cymbiotika, RHO, Renue by Science, Goldman Laboratories, and other manufacturers.
Products may be available in the form of liquids, capsules, drops, sachets, or single-serving portions.
However, the presence of the term „liposomal” does not mean that all these products are equivalent.
The quality of the liposomal formulation can vary significantly.
Key variables include:
- lipid composition;
- particle size;
- production technique;
- encapsulation efficiency;
- product stability;
- percentage of declared NAD+ actually encapsulated in liposomes.
These factors may affect the behavior of a specific formulation.
Results pertaining to a specific laboratory formulation should not be automatically applied to every commercial product labeled as liposomal NAD+.
Individual products may differ in lipid composition, particle size, stability, encapsulation efficiency, and actual NAD+ content.
A similar issue applies more broadly to NR and NMN supplements.
Clinical trials often use a specific compound or formulation of research-grade quality.
Consumer products may contain the same general ingredient, but they do not have to be produced or characterized in an identical manner.
What is worth checking when comparing products?
One useful factor to consider is whether the manufacturer provides actual data on the size of the liposomal particles.
Simply including the word „liposomal” on the label does not confirm the presence of a stable and well-characterized liposomal system.
Another important parameter is the encapsulation efficiency.
It indicates what part of the active NAD+ is actually inside the liposomes and what part remains free in the surrounding fluid.
Independent analytical research may also be useful.
A certificate of analysis (CoA) can help confirm whether the amount of NAD+ in a product matches the value stated on the label.
The exact active substance must also be verified.
Some products widely promoted as liposomal NAD+ may actually contain an NAD+ precursor, such as NMN, instead of unmodified NAD+.
This distinction matters because the evidence base for unmodified NAD+, NMN, and NR is not the same.
Production transparency is also important.
Information on the origin of raw materials, quality control procedures, stability testing, and manufacturing in compliance with Good Manufacturing Practice standards can help distinguish a well-characterized formulation from a product relying primarily on marketing terminology.
Does liposomal NAD+ justify the higher price?
Liposomal NAD+ is usually more expensive than standard oral NR or NMN.
The higher price is partly due to the additional production steps required to create and stabilize the lipid delivery system.
However, it is unclear whether this price difference is scientifically justified.
Why might a higher cost be justified?
The concept of delivery makes sense from a chemical standpoint.
Unmodified NAD+ is a large, charged, water-soluble molecule that undergoes metabolic changes in the gastrointestinal tract.
Encapsulating it within lipid structures is a reasonable attempt to mitigate some of these problems.
Cell culture studies also suggest that, under experimental conditions, liposomal NAD+ may produce stronger cellular effects than NAD+ without a liposomal formulation. [5]
These results support the biological plausibility of the formulation, but do not confirm its bioavailability or clinical benefits in humans.
Why should we be cautious about higher prices?
Direct human studies on liposomal NAD+ remain very limited.
There is a lack of properly designed, peer-reviewed clinical studies confirming that this formulation provides significant benefits in terms of biomarkers, well-being, or functional health outcomes.
There is also no completed, peer-reviewed comparative study showing that liposomal NAD+ increases NAD+ levels more effectively than NR or NMN.
Such a comparison is important because NR and NMN already have a much larger base of randomized human trials. [3,4]
The lack of direct comparative data also means that it is not possible to reliably calculate whether liposomal NAD+ provides a greater increase in NAD+ relative to the money spent.
The quality of commercial formulations can also vary.
Two products don't have to work the same way just because both are sold as liposomal.
The conclusion based on the current evidence is relatively simple.
If the priority is choosing an oral NAD+-related product with the largest and most mature body of human research, NR and NMN are currently better documented.
If the interest is specifically in delivering unmodified NAD+ via a potentially protective lipid system, liposomal NAD+ represents a biologically plausible, yet still experimental concept.
It should not be described as a method with confirmed bioavailability, clinical efficacy, or superiority over standard NAD+ precursors.
Liposomal NAD+: Evidence in Brief
| Research question | Current evidence |
|---|---|
| Does unchanged oral NAD+ encounter absorption issues? | Yes, due to their molecular weight, charge, and metabolism [1,2] |
| Can liposomes protect water-soluble compounds? | Yes, as a general principle for the formulation and delivery of drugs |
| Is liposomal NAD+ a biologically plausible concept? | Yes |
| Has an increase in intracellular NAD+ been confirmed in humans? | There is insufficient peer-reviewed research to support this conclusion |
| Has it been shown that liposomal NAD+ improves energy or well-being? | Not |
| Are there supportive studies on cell cultures? | Yes [5] |
| Has liposomal NAD+ been directly compared to NR or NMN in a matched human study? | Not established |
| Has a clinical advantage over standard capsules been demonstrated? | Not |
| Are all commercial liposomal NAD+ products equivalent? | There is no evidence to support such an assumption |
| Has the cost-effectiveness of a higher price been scientifically proven? | Not established |
Frequently asked questions about liposomal NAD+
What is liposomal NAD+?
Liposomal NAD+ is NAD+ enclosed in microscopic lipid structures called liposomes.
The purpose of this formulation is to protect the molecule as it passes through the gastrointestinal tract and to potentially improve its absorption or delivery to cells.
Why is NAD+ placed in liposomes?
Unmodified NAD+ is relatively large, highly charged, and water-soluble.
These properties hinder simple passive intestinal absorption.
Liposomal encapsulation is intended to protect the molecule and potentially improve its delivery.
Is liposomal NAD+ better absorbed?
This has not been confirmed in properly designed, peer-reviewed comparative studies involving humans.
Lipid encapsulation can theoretically protect NAD+ and influence its delivery. However, there is a lack of head-to-head studies confirming greater bioavailability compared to standard NAD+, NR, or NMN.
Is liposomal NAD+ better than NMN?
This has not been demonstrated.
NMN has a larger body of randomized human studies evaluating NAD+-related biomarkers. [3]
Liposomal NAD+ has mechanistic and laboratory support, but its clinical advantage over NMN has not been confirmed.
Is liposomal NAD+ better than NR?
There is insufficient evidence to confirm such an advantage.
NR has been evaluated in numerous randomized, placebo-controlled trials, whereas direct clinical data on liposomal NAD+ remain much more limited. [4]
Does liposomal NAD+ increase energy?
This has not been demonstrated in reliable clinical trials.
A probable biological mechanism or an effect observed in cultured cells does not automatically confirm increased energy, improved performance, or enhanced well-being in humans.
Are all brands of liposomal NAD+ the same?
No.
The composition of liposomes, particle size, encapsulation efficiency, stability, ingredient quality, and manufacturing processes may vary among brands.
Results for one specific formulation cannot be automatically applied to every commercial product.
What to look for when choosing a liposomal NAD+ product?
Useful information may include:
- the specific active ingredient;
- declared NAD+ content;
- independent laboratory testing;
- certificate of analysis;
- liposomal particle size data;
- encapsulation efficiency;
- stability data;
- transparent production standards.
The word „liposomal” alone provides very little information about the actual quality of the formulation.
Limitations of current evidence
The most significant limitation is the lack of a sufficient number of peer-reviewed clinical studies specifically evaluating liposomal NAD+.
The current rationale is based primarily on the chemical properties of NAD+, general principles of liposomal formulations, and laboratory experiments.
Another limitation is the lack of direct comparisons.
Among the cited publications, there is no completed, peer-reviewed human study that directly compares liposomal NAD+ with NR, NMN, or standard non-liposomal NAD+ at matched doses and with the same pharmacokinetic endpoints.
This prevents drawing definitive conclusions regarding relative bioavailability.
Supporting mechanistic evidence also includes in vitro studies. [5]
Cell culture results can support the biological plausibility of the mechanism, but they do not reproduce digestion, hepatic metabolism, systemic circulation, tissue distribution, or full human physiology.
Another limitation is the differences between commercial products.
Results for a specific laboratory formulation should not be automatically generalized to Quicksilver Scientific, Cymbiotika, RHO, Renue by Science, Goldman Laboratories, or other brands unless that exact product has been independently tested.
The quality of the formulation may also vary.
Liposome size, lipid composition, encapsulation efficiency, product stability, and actual NAD+ content are not always disclosed by manufacturers to the same extent.
The cost-effectiveness of this delivery method has also not been established.
Without properly matched human studies, there is no strong evidence showing that the higher price of liposomal NAD+ translates to proportionally greater bioavailability or better clinical outcomes than cheaper oral NR or NMN.
Current evidence therefore allows liposomal NAD+ to be described as a biologically plausible delivery method supported by laboratory data, but not as a confirmed alternative superior to more established oral NAD+ precursors.
Disclaimer
The article is for educational and scientific-information purposes only. It does not constitute medical advice, therapeutic recommendations, dosage instructions, product recommendations, or an endorsement of liposomal NAD+, standard NAD+, NR, NMN, or any of the mentioned commercial brands.
Liposomal NAD+ has a plausible mechanistic rationale as a delivery method, but there is a lack of sufficient peer-reviewed clinical evidence confirming its bioavailability or benefits in humans. Laboratory results should not be interpreted as proof of better absorption, improved clinical outcomes, anti-aging effects, or greater efficacy compared to standard NAD+ precursors.
NAD+ and related products are not approved by the FDA or EMA to treat, prevent, or cure diseases. Brand names are provided solely to describe products available on the market. Their mention does not imply independent clinical validation, recommendation, or equivalence to any specific liposomal formulation used in scientific research.
References
[1] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[2] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
[3] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[4] Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. https://doi.org/10.1038/s41467-018-03421-7
[5] Ministrini, S., Liberale, L., Erle, H.-E., Percoco, G., Tfayli, A., Assi, A., Kapitonov, I., Greiner, I., & Camici, G. G. (2025). A liposomal formulation enhances the anti-senescence properties of nicotinamide adenine-dinucleotide (NAD+) in endothelial cells and keratinocytes. Current Issues in Molecular Biology, 47(9), 722. https://doi.org/10.3390/cimb47090722